- Home
- EDRY vs XLO Comparison
EDRY vs XLO Comparison
Compare EDRY & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDRY
- XLO
- Stock Information
- Founded
- EDRY 2018
- XLO 2016
- Country
- EDRY Greece
- XLO United States
- Employees
- EDRY N/A
- XLO N/A
- Industry
- EDRY Marine Transportation
- XLO Biotechnology: Pharmaceutical Preparations
- Sector
- EDRY Consumer Discretionary
- XLO Health Care
- Exchange
- EDRY Nasdaq
- XLO Nasdaq
- Market Cap
- EDRY 31.7M
- XLO 37.9M
- IPO Year
- EDRY N/A
- XLO 2021
- Fundamental
- Price
- EDRY $10.50
- XLO $0.93
- Analyst Decision
- EDRY
- XLO Buy
- Analyst Count
- EDRY 0
- XLO 1
- Target Price
- EDRY N/A
- XLO $4.00
- AVG Volume (30 Days)
- EDRY 9.5K
- XLO 10.5M
- Earning Date
- EDRY 02-24-2025
- XLO 03-31-2025
- Dividend Yield
- EDRY N/A
- XLO N/A
- EPS Growth
- EDRY N/A
- XLO N/A
- EPS
- EDRY N/A
- XLO N/A
- Revenue
- EDRY $65,085,280.00
- XLO $4,620,000.00
- Revenue This Year
- EDRY $31.96
- XLO N/A
- Revenue Next Year
- EDRY $5.32
- XLO $558.79
- P/E Ratio
- EDRY N/A
- XLO N/A
- Revenue Growth
- EDRY 39.04
- XLO N/A
- 52 Week Low
- EDRY $10.04
- XLO $0.55
- 52 Week High
- EDRY $24.84
- XLO $1.93
- Technical
- Relative Strength Index (RSI)
- EDRY 39.27
- XLO 48.99
- Support Level
- EDRY $10.40
- XLO $0.97
- Resistance Level
- EDRY $10.83
- XLO $1.22
- Average True Range (ATR)
- EDRY 0.51
- XLO 0.14
- MACD
- EDRY 0.01
- XLO 0.03
- Stochastic Oscillator
- EDRY 7.58
- XLO 28.04
About EDRY EuroDry Ltd.
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulks such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers.
About XLO Xilio Therapeutics Inc.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).